ClinicalTrials.Veeva

Menu

Expanded Access to Glecaprevir/ Pibrentasvir

AbbVie logo

AbbVie

Status

Conditions

Hepatitis C Virus Infection

Treatments

Drug: pibrentasvir
Drug: glecaprevir

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT03123965
C16-563

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems